Anticorps Recombinant de lapin anti-KMT2C
KMT2C Recombinant Antibody for IF/ICC, FC (Intra), ELISA
Hôte / Isotype
Lapin / IgG
Réactivité testée
Humain
Applications
IF/ICC, FC (Intra), ELISA
Conjugaison
Non conjugué
CloneNo.
240542A2
N° de cat : 83595-4-RR
Synonymes
Galerie de données de validation
Applications testées
| Résultats positifs en IF/ICC | cellules MCF-7, |
| Résultats positifs en FC (Intra) | cellules U2OS, |
Dilution recommandée
| Application | Dilution |
|---|---|
| Immunofluorescence (IF)/ICC | IF/ICC : 1:125-1:500 |
| Flow Cytometry (FC) (INTRA) | FC (INTRA) : 0.25 ug per 10^6 cells in a 100 µl suspension |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Informations sur le produit
83595-4-RR cible KMT2C dans les applications de IF/ICC, FC (Intra), ELISA et montre une réactivité avec des échantillons Humain
| Réactivité | Humain |
| Hôte / Isotype | Lapin / IgG |
| Clonalité | Recombinant |
| Type | Anticorps |
| Immunogène | KMT2C Protéine recombinante Ag28875 |
| Nom complet | myeloid/lymphoid or mixed-lineage leukemia 3 |
| Masse moléculaire calculée | 541 kDa |
| Numéro d’acquisition GenBank | NM_170606 |
| Symbole du gène | KMT2C |
| Identification du gène (NCBI) | 58508 |
| Conjugaison | Non conjugué |
| Forme | Liquide |
| Méthode de purification | Protein A purfication |
| Tampon de stockage | PBS with 0.02% sodium azide and 50% glycerol |
| Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. |
Informations générales
Lysine (K)-specific methyltransferase 2C (KMT2C, also known as MLL3) belongs to the mixed-lineage leukemia (MLL) family of histone methyltransferases which methylate the histone 3 tail at lysine 4 (H3K4) as part of the complex proteins associated with Set 1 (COMPASS) complex. Although originally identified as oncogenic fusions in leukemia, genome-wide mutation studies have revealed frequent, presumably loss-of-function, mutations in various members of the MLL family, including MLL2/KMT2B, MLL3/KMT2C, and MLL4/KMT2D in a variety of malignancies, particularly solid tumors. Mechanistic studies of KMT2C in normal cells have focused primarily on its role in enhancer regulation by deposition of H3K4me1 marks.
Protocole
| Product Specific Protocols | |
|---|---|
| IF protocol for KMT2C antibody 83595-4-RR | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |



